SWP
RLMD icon

Stratos Wealth Partners’s Relmada Therapeutics RLMD Stock Holding History

Stratos Wealth Partners’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-14,100
Closed -$65.6K – 1434
2024
Q1 		$65.6K Sell
14,100
-2,400
-15% -$11.6K ﹤0.01% 1352
2023
Q4 		$68.3K Buy
16,500
+500
+3% +$1.48K ﹤0.01% 1334
2023
Q3 		$48K Buy
+16,000
New +$47.5K ﹤0.01% 1255

Other funds holding RLMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Stratos Wealth Partners's RLMD Position: Q2 2024 in Review

Stratos Wealth Partners sold out of Relmada Therapeutics (RLMD) in Q2 2024, closing a stake of 14,100 shares — an estimated $65.6K sold.

Stratos Wealth Partners first reported a position in RLMD in Q3 2023 and held it in 3 quarters. The position peaked at $68.3K in Q4 2023. 79 funds tracked by Wall St. Rank hold RLMD as of Q2 2024.

  • Stratos Wealth Partners reported no remaining Relmada Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Stratos Wealth Partners sold 14,100 Relmada Therapeutics shares in Q2 2024, an estimated $65.6K.
  • Stratos Wealth Partners first reported a position in Relmada Therapeutics in Q3 2023 and held it in 3 quarters.
  • Stratos Wealth Partners's Relmada Therapeutics position peaked at $68.3K in Q4 2023.
  • 79 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2024.

Based on Stratos Wealth Partners's 13F filing for Q2 2024, filed 24 Jul 2024.